Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. - Wikidata - wikimedia - TriplyDB

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

http://www.wikidata.org/entity/Q34111744

about

Targeting folate receptor alpha for cancer treatment Profile of farletuzumab and its potential in the treatment of solid tumors A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review Farletuzumab in lung cancer Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy Antigen-specific immunotherapy of cervical and ovarian cancer Targeted immune therapy of ovarian cancer A current review of targeted therapeutics for ovarian cancer.Antibodies to watch in 2010 A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity.Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.Have we overestimated the benefit of human(ized) antibodies?Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Immunity and immune suppression in human ovarian cancer.A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo Characterization of the human folate receptor alpha via novel antibody-based probes.Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha.Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance.High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation Clinical utility of targeted treatments in the management of epithelial ovarian cancer.Assessment of molecular interactions through magnetic relaxation.Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.Role of farletuzumab in epithelial ovarian carcinoma.Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease.Intraoperative imaging in ovarian cancer: fact or fiction?Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.Prospects in folate receptor-targeted radionuclide therapy Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Folate receptor alpha as a tumor target in epithelial ovarian cancer Folate-immunoglobulin G as an anticancer therapeutic antibody.Intraoperative molecular imaging to identify lung adenocarcinomas.The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.Autoantibodies to folate receptor during pregnancy and neural tube defect risk.

P2860

Q26744215-174BFCB1-7CFD-455A-B4F4-047448E1E3A4 Q26750431-C82726E3-4A02-4F94-A0FC-4FEDC44821C2 Q26781856-7702C748-F9BB-47F9-B122-75AE44FEE483 Q26828581-96B61CEE-5DB7-4F87-B83A-1DE14FAB3CEB Q26997008-7879BB37-6F2B-4428-B3D7-48D5977FB6C9 Q27005742-C3F13B71-EEA3-4EFC-93C0-D94000539336 Q27488697-6CC7A279-9F78-4838-8415-D3A7DDA73038 Q28082828-B0F54840-753C-4F37-8741-F37D0273D0ED Q33580998-EB8FD6D0-34FE-48BA-92BD-F77AB4E1B6C2 Q33688243-E8FA2436-822D-44F7-A046-3E0171EFCC30 Q33866381-B07482B4-A9FF-4B48-9484-3643F3AB005F Q33900573-6A56C604-E271-468E-AF88-8D34BECCDF0A Q34142714-6BB4A235-E40B-478E-A0E0-6AF2744352B9 Q34687073-9784A1D6-8B6C-48BB-9300-18007590FD3C Q34979610-A51D053A-8E22-46E8-8C1D-B3F4D43171C8 Q35088311-46D269EE-1E85-46EA-B3C1-F842D6C4772C Q35138135-C8B563AD-6D6B-4AF8-9C8E-77283D7EDBAD Q35288804-D44CBC8C-CB1C-4D19-B714-7BE1D26F9812 Q35298302-CA51D7A6-BFC4-4787-8E9B-5786D2AEDDC9 Q35764371-9EC43845-5206-4DAA-A1B9-71EAB120D163 Q35915267-52672F9D-6209-4A08-8242-79BFEFC80189 Q36050687-2CF218F8-E46A-4BFA-BABE-D1C51634F5D9 Q36059727-185D05A3-990A-4303-9213-D8369FA10FB6 Q36171268-C79D3DFB-E0BF-492F-8F36-638F234F1EBF Q36290548-25C7C6CE-ABCF-46C1-9E82-FB72A41AEDFA Q36361160-93FB603E-6D5F-40D4-BCF8-FCF626E01741 Q36508941-4C09FA56-5B9E-4E6E-B708-EB2033BBD05C Q36622914-7149B4D7-F3DA-421F-9F93-55AE95752379 Q36821156-F442B5D2-C7D4-4A3B-A6D1-740369EC14D5 Q37052124-5ED2916B-37C5-4F67-940B-4CFB9AD48ED8 Q37149571-BDD413BE-BCEF-4BB1-86C6-C3DADD7602A0 Q37178234-F7AC84FA-6C13-47F4-9361-C30937F8BFBE Q37193061-33A8211E-518E-4CCD-828E-9A3437E70B83 Q37220528-9C5BEC63-409E-4824-B0A5-86D0EDC3DBB4 Q37254805-E2977F8D-02B5-404B-B071-C030F82866F3 Q37267004-2DFB1507-E6B8-46FF-8852-CF73B7073814 Q37528105-17CBDDF0-88CE-431B-969C-2356A4330CEF Q37586901-F50CEB70-66A0-4447-83D1-54877BE2C8DA Q37685630-AB5BF732-5D1B-4483-9F28-675A3578BD53 Q37721045-677B00AA-DEF6-4DAA-A348-027F95F31F85

P2860

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

http://www.wikidata.org/entity/Q34111744

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@ast

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@en

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@nl

type

label

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@ast

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@en

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@nl

prefLabel

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@ast

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@en

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@nl

P1433

Q34111744-ABE00FFB-00F2-4E37-ADCB-869FCD3E70F5

P1476

Q34111744-91D25110-F57A-4090-8EA9-62487BE4D84E

P2093

Q34111744-070620DA-9EC6-4875-B6D8-AEFBE9E1E628

Q34111744-153B1303-B4D8-496B-8848-4CDE77ABC98A

Q34111744-31EEF02F-EEF0-4B51-8AC9-DC3F23558900

Q34111744-3704B93B-5ECE-41EE-AE9C-AD0EE51BE48F

Q34111744-3ADED5C2-2869-4407-89CE-A6B8F1506EFF

Q34111744-3BBCAD21-F8FC-44B3-9A30-7CCDAC7F0DEF

Q34111744-4A8E7E82-7927-4D87-9866-F959F641414E

Q34111744-6784D55C-8F20-4CD4-A956-B75A1F211868

Q34111744-97CC3D2E-9E1C-413A-AB4C-75AEAD76C9A2

Q34111744-A19032D2-8F2C-4367-A164-392EF43F36A5

P2860

Q34111744-0D6A8CED-1409-41DC-9923-0615A5E0C10E

Q34111744-14E38563-DE3E-40CA-8018-4416DD63CBA0

Q34111744-19A5784C-92E5-4C75-BD92-16E8629D2FDF

Q34111744-1BEDC3B8-89E6-46BA-BD92-93FA568D0E15

Q34111744-48F3F025-82D7-429C-BF1A-E98D970B35D6

Q34111744-4DF09177-EEE7-413F-83BF-FD6D4E5F836D

Q34111744-5121A1CC-E4F8-4812-8744-8756768C6100

Q34111744-592C4B18-B62C-4AA5-B435-0F20E0BA7095

Q34111744-5DBA221F-66EE-4B64-8C79-A380499794D0

Q34111744-60DAF36A-8C8B-42CD-901F-CB67B91631B7

P304

Q34111744-DA481CD3-3DDC-496C-A058-2674FBD9816F

P31

Q34111744-2D6C75B4-99A3-4DC3-94BC-95AA1C59ABE2

P478

Q34111744-A37F99C0-1DE0-4DB2-8C60-7CF16ACBDF3F

P577

Q34111744-472A21C0-DC8D-40A5-8482-1AA6AE859B3E

P698

Q34111744-288535F0-3D93-4901-8A67-8DABD39AEEB1

P921

Q34111744-091048B6-DFC6-4BF8-B64E-F2240DDE8EF4

P932

Q34111744-80293AD2-ACF5-4ABD-98AE-94973E24D67E

P1433

Cancer Immunity

P1476

Preclinical evaluation of MORA ...... onizing folate receptor-alpha.

@en

P2093

Brian Foley

http://www.w3.org/2001/XMLSchema#string

Eric L Routhier

http://www.w3.org/2001/XMLSchema#string

Howard A Turchin

http://www.w3.org/2001/XMLSchema#string

J Bradford Kline

http://www.w3.org/2001/XMLSchema#string

Jennifer M McDonough

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Luigi Grasso

http://www.w3.org/2001/XMLSchema#string

Martin D Phillips

http://www.w3.org/2001/XMLSchema#string

Nicholas C Nicolaides

http://www.w3.org/2001/XMLSchema#string

Philip M Sass

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1

Folate-binding protein is a marker for ovarian cancer

Morphogenics as a tool for target discovery and drug development.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate.

Overexpression of folate binding protein in ovarian cancers.

Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.

Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.

Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.

Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts.

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17346028

http://www.w3.org/2001/XMLSchema#string

P921

P932

2935753

http://www.w3.org/2001/XMLSchema#string